TARDBP and hepatocellular carcinoma: It inhibits the expression of microRNA520, which subsequently affects the expression of platelet subtypes of phosphofructokinase, thereby modulating the glycolysis process in hepatocellular carcinoma.[32] Additionally, TARDBP may facilitate the migration of lung cancer cells by regulating miR-423-3p.